Cascadian Therapeutics Incorporated (NASDAQ:CASC) Can’t Be More Risky. Short Interest Increased

September 17, 2017 - By Darrin Black

 Cascadian Therapeutics Incorporated (NASDAQ:CASC) Can't Be More Risky. Short Interest Increased

The stock of Cascadian Therapeutics Incorporated (NASDAQ:CASC) registered an increase of 0.24% in short interest. CASC’s total short interest was 2.29M shares in September as published by FINRA. Its up 0.24% from 2.28M shares, reported previously. With 262,700 shares average volume, it will take short sellers 9 days to cover their CASC’s short positions. The short interest to Cascadian Therapeutics Incorporated’s float is 7.22%.

The stock increased 4.09% or $0.15 on September 15, reaching $3.82. About 847,604 shares traded or 164.62% up from the average. Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) has declined 30.85% since September 17, 2016 and is downtrending. It has underperformed by 47.55% the S&P500.

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The company has market cap of $193.11 million. The Firm focuses on the development of therapeutic products for the treatment of cancer. It currently has negative earnings. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor 2 inhibitor.

More notable recent Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) news were published by: Seekingalpha.com which released: “Cascadian Therapeutics: Worth Much More Than The Present Share Price” on March 23, 2017, also Globenewswire.com with their article: “Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress” published on January 05, 2017, Globenewswire.com published: “Cascadian Therapeutics Announces Positive Regulatory Update for Tucatinib in …” on July 11, 2017. More interesting news about Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) were released by: Globenewswire.com and their article: “Cascadian Therapeutics Appoints Dr. Marc L. Lesnick as Senior Vice President …” published on January 04, 2017 as well as Seekingalpha.com‘s news article titled: “Cascadian Therapeutics’ (CASC) CEO Scott Myers on Q1 2017 Results – Earnings …” with publication date: May 09, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.